Adoptive cell therapy for the treatment of patients with metastatic melanoma.
about
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastomaEradication of melanomas by targeted elimination of a minor subset of tumor cellsInvolvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanomaDendritic Polymers for TheranosticsEffects of Alcohol on Tumor Growth, Metastasis, Immune Response, and Host SurvivalAdoptive T-Cell ImmunotherapyAdoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlookInnate and adaptive immune cells in the tumor microenvironmentClinical application of adoptive T cell therapy in solid tumorsTumor infiltrating lymphocytes in ovarian cancerCurrent translational and clinical practices in hematopoietic cell and gene therapyUltrasound-mediated targeted drug delivery: recent success and remaining challengesCancer immunotherapyTCRs Used in Cancer Gene Therapy Cross-React with MART-1/Melan-A Tumor Antigens via Distinct MechanismsPeptide length determines the outcome of TCR/peptide-MHCI engagementTargeted immune therapy of ovarian cancerTumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome.Dendritic cells transfected with Her2 antigen-encoding RNA replicons cross-prime CD8 T cells and protect mice against tumor challenge.MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia.Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanomaRandomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccineInterface of signal transduction inhibition and immunotherapy in melanoma.Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies.Tumor immunity against a simian virus 40 oncoprotein requires CD8+ T lymphocytes in the effector immune phaseAntibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice.What's the place of immunotherapy in malignant mesothelioma treatments?High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cellsMelanoma: a model for testing new agents in combination therapies.CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells.Differences in TCR-Vβ repertoire and effector phenotype between tumor infiltrating lymphocytes and peripheral blood lymphocytes increase with age.Chronic alcohol consumption enhances myeloid-derived suppressor cells in B16BL6 melanoma-bearing mice.BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in miceWhole-body irradiation increases the magnitude and persistence of adoptively transferred T cells associated with tumor regression in a mouse model of prostate cancerAntiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.CAR-modified T-cell therapy for cancer: an updated review.Alloantigen-specific regulatory T cells generated with a chimeric antigen receptorEx vivo expansion of human CD8+ T cells using autologous CD4+ T cell helpRedirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection.
P2860
Q24602657-BFC9C3C2-B0C3-4B04-8CE1-203B4279A4F4Q24624761-54389066-C50C-4D3B-ACEA-78A201C83C94Q24649754-0FFF66CE-8BBA-4BFC-A6C1-8B7D11E6085CQ26746182-1199A8E6-3878-4AFA-A9DC-C1695228E1F7Q26773212-AFA1614E-433A-42C2-8E99-2E4654055901Q26782845-324B0C54-2E13-44A1-8A81-E5BD5DBD91B1Q27004178-FFB608B3-1272-408C-9E07-9EC8AF174AA8Q27008342-B5153784-DBD7-4A90-BD2D-9D3ADEF6D9E1Q27011283-136C950B-DC50-40A0-AEC8-DC44C5AB45C4Q27021878-4DB8DC02-168C-4FC2-9046-25ED6B9CED5DQ27024456-B3FF38AF-E2F5-4558-90C4-A5CEF0E0F208Q27026689-B2716060-11D4-484D-B99C-C00521C2137EQ27026870-4A854063-26E7-4C36-B355-76AA8755B104Q27671024-2771159D-A5BD-49A8-93B8-5C6EF09F80A2Q27675544-EBC1D921-8752-4430-9894-881A309060CBQ28082828-1791A820-5436-4F35-A168-482836BE737AQ29616128-DEC348EA-3EA4-4238-AEF3-DADDACF72169Q30275174-B64D6E27-7456-46A8-BC4B-6CF94EC6EAC2Q30318566-CB59A25A-BF85-44CA-A194-78659E7C7D0FQ30412320-D08164EE-4EB6-42BE-A83D-767ED8CBB273Q30422102-ECF8658C-28AD-47B7-A1DE-B85D5E4CDDBBQ30425914-32A9B6DC-B7A2-4397-938D-56F98A73609EQ30429380-E403E849-C34F-4E3E-9017-647FD0A0D168Q33357295-5DFE63A9-3E2D-40EB-B635-D5F37BA14EAFQ33530527-051B0B43-A6D2-430F-A0CE-C100E6AF68C3Q33558482-D496F335-F5BF-41FA-925F-446174929E25Q33560416-05C52B68-5376-4714-92E0-36E91018C97DQ33781142-FDC8080C-60B1-46FD-A0B2-9524C38FD19AQ33806895-6EB9E4B8-CE98-48E3-A13B-8810E17FAA10Q33863916-062F1250-EAD3-40A1-B56A-8F172B32AE24Q33867018-8313E296-F989-4A97-93DB-F9693624357FQ33895977-869B7DF0-3EE0-4885-8294-C893918430D7Q33898612-315FF4E1-CAD7-4636-BF7E-A8198E306D1EQ33996674-DC35BE56-3DB5-4D89-9126-6C144C5D98C8Q34016750-F21D8306-2977-428C-9C2D-09ED67D648A6Q34031748-6DBCCEA5-65B4-4B16-B307-F3C4AAF441BDQ34044213-1BE23A1B-92AA-48DE-AEA6-165ED55785E1Q34046489-DE27F4BA-82DB-4EF9-A125-4B1495687AE8Q34141754-4A1FDB54-CF1C-4B40-9ABD-B0A4C952AFC9Q34166288-032E50D4-7786-4A1D-B189-78229406FCBB
P2860
Adoptive cell therapy for the treatment of patients with metastatic melanoma.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Adoptive cell therapy for the treatment of patients with metastatic melanoma.
@ast
Adoptive cell therapy for the treatment of patients with metastatic melanoma.
@en
type
label
Adoptive cell therapy for the treatment of patients with metastatic melanoma.
@ast
Adoptive cell therapy for the treatment of patients with metastatic melanoma.
@en
prefLabel
Adoptive cell therapy for the treatment of patients with metastatic melanoma.
@ast
Adoptive cell therapy for the treatment of patients with metastatic melanoma.
@en
P2860
P1476
Adoptive cell therapy for the treatment of patients with metastatic melanoma.
@en
P2093
Mark E Dudley
Steven A Rosenberg
P2860
P304
P356
10.1016/J.COI.2009.03.002
P577
2009-03-21T00:00:00Z